Skip to main content
SpringerLink
Log in

Influenza A Virus Neuraminidase Inhibitors

  • Protocol
  • First Online:
Glycovirology

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2556))

Abstract

Depending on the strain, influenza A virus causes animal, zoonotic, pandemic, or seasonal influenza with varying degrees of severity. Two surface glycoprotein spikes, hemagglutinin (HA) and neuraminidase (NA), are the most important influenza A virus antigens. NA plays an important role in the propagation of influenza virus by removing terminal sialic acid from sialyl decoy receptors and thereby facilitating the release of viruses from traps such as in mucus and on infected cells. Some NA inhibitors have become widely used drugs for treatment of influenza. However, attempts to develop effective and safe NA inhibitors that can be used for treatment of anti-NA drugs-resistant influenza viruses have continued. In this chapter, we describe the following updates on influenza A NA inhibitor development: (i) N-acetylneuraminic acid (Neu5Ac)-based derivatives, (ii) covalent NA inhibitors, (iii) sulfo-sialic acid analogs, (iv) N-acetyl-6-sulfo-β-d-glucosaminide-based inhibitors, (v) inhibitors targeting the 150-loop of group 1 NAs, (vi) conjugation inhibitors, (vii) acylhydrazone derivatives, (viii) monoclonal antibodies, (ix) PVP-I, and (x) natural products. Finally, we provide future perspectives on the next-generation anti-NA drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. ICTV Website (2021) Virus taxonomy: 2020 release. https://talk.ictvonline.org/ictv-reports/ictv_9th_report/negative-sense-rna-viruses-2011/w/negrna_viruses/209/orthomyxoviridae

  2. Tong S, Zhu X, Li Y et al (2013) New world bats harbor diverse influenza A viruses. PLoS Pathog 9:e1003657

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sriwilaijaroen N, Suzuki Y (2020) Host receptors of influenza viruses and coronaviruses-molecular mechanisms of recognition. Vaccines (Basel) 8:587

    Article  CAS  Google Scholar 

  4. WHO Website (2021) Influenza – estimating burden of disease. https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/seasonal-influenza/burden-of-influenza

  5. Wang K, Lei Z, Zhao L et al (2020) Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A. Eur J Med Chem 185:111841

    Article  CAS  PubMed  Google Scholar 

  6. de Vries E, Du W, Guo H et al (2020) Influenza A virus hemagglutinin-neuraminidase-receptor balance: preserving virus motility. Trends Microbiol 28:57–67

    Article  PubMed  Google Scholar 

  7. Kiefel MJ, von Itzstein M (1999) Influenza virus sialidase: a target for drug discovery. Prog Med Chem 36:1–28

    Article  CAS  PubMed  Google Scholar 

  8. von Itzstein M, Wu WY, Kok GB et al (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418–423

    Article  Google Scholar 

  9. Kim CU, Lew W, Williams MA et al (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119:681–690

    Article  CAS  PubMed  Google Scholar 

  10. Babu YS, Chand P, Bantia S et al (2000) BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43:3482–3486

    Article  CAS  PubMed  Google Scholar 

  11. Yamashita M, Tomozawa T, Kakuta M et al (2009) CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53:186–192

    Article  CAS  PubMed  Google Scholar 

  12. Shidmoossavee FS, Watson JN, Bennet AJ (2013) Chemical insight into the emergence of influenza virus strains that are resistant to Relenza. J Am Chem Soc 135:13254–13257

    Article  CAS  PubMed  Google Scholar 

  13. Moscona A (2005) Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 353:2633–2636

    Article  CAS  PubMed  Google Scholar 

  14. Hurt AC, Holien JK, Parker M et al (2009) Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 83:10366–10373

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Nitsch-Osuch A, Brydak LB (2014) Influenza viruses resistant to neuraminidase inhibitors. Acta Biochim Pol 61:505–508

    Article  PubMed  Google Scholar 

  16. Memoli MJ, Hrabal RJ, Hassantoufighi A et al (2010) Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 50:1252–1255

    Article  CAS  PubMed  Google Scholar 

  17. L’Huillier AG, Abed Y, Petty TJ et al (2015) E119D neuraminidase mutation conferring pan-resistance to neuraminidase inhibitors in an A(H1N1)pdm09 isolate from a stem-cell transplant recipient. J Infect Dis 212:1726–1734

    Article  PubMed  PubMed Central  Google Scholar 

  18. Matrosovich MN, Klenk HD, Kawaoka Y (2006) Receptor specificity, host-range, and pathogenicity of influenza viruses. In: Kawaoka Y (ed) Influenza virology: current topics. Caister Academic Press, Wymondham, pp 95–137

    Google Scholar 

  19. Sriwilaijaroen N, Suzuki Y (2020) Sialoglycovirology of lectins: sialyl glycan binding of enveloped and non-enveloped viruses. Methods Mol Biol 2132:483–545

    Article  CAS  PubMed  Google Scholar 

  20. McAuley JL, Corcilius L, Tan HX et al (2017) The cell surface mucin MUC1 limits the severity of influenza A virus infection. Mucosal Immunol 10:1581–1593

    Article  CAS  PubMed  Google Scholar 

  21. Matrosovich MN, Matrosovich TY, Gray T et al (2004) Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78:12665–12667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ohuchi M, Asaoka N, Sakai T et al (2006) Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect 8:1287–1293

    Article  CAS  PubMed  Google Scholar 

  23. McAuley JL, Gilbertson BP, Trifkovic S et al (2019) Influenza virus neuraminidase structure and functions. Front Microbiol 10:39

    Article  PubMed  PubMed Central  Google Scholar 

  24. Yagi H, Watanabe S, Suzuki T et al (2012) Comparative analyses of N-glycosylation profiles of influenza A viruses grown in different host cells. Open Glycosci 5:2–12

    Article  CAS  Google Scholar 

  25. Palese P, Compans RW (1976) Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 33:159–163

    Article  CAS  PubMed  Google Scholar 

  26. Xu R, Zhu X, McBride R et al (2012) Functional balance of the hemagglutinin and neuraminidase activities accompanies the emergence of the 2009 H1N1 influenza pandemic. J Virol 86:9221–9232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Du W, Wolfert MA, Peeters B et al (2020) Mutation of the second sialic acid-binding site of influenza A virus neuraminidase drives compensatory mutations in hemagglutinin. PLoS Pathog 16:e1008816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. da Silva DV, Nordholm J, Madjo U et al (2013) Assembly of subtype 1 influenza neuraminidase is driven by both the transmembrane and head domains. J Biol Chem 288:644–653

    Article  PubMed  Google Scholar 

  29. Wang M, Qi J, Liu Y et al (2011) Influenza A virus N5 neuraminidase has an extended 150-cavity. J Virol 85:8431–8435

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Sun X, Li Q, Wu Y et al (2014) Structure of influenza virus N7: the last piece of the neuraminidase “jigsaw” puzzle. J Virol 88:9197–9207

    Article  PubMed  PubMed Central  Google Scholar 

  31. Du W, Dai M, Li Z et al (2018) Substrate binding by the second sialic acid-binding site of influenza A virus N1 neuraminidase contributes to enzymatic activity. J Virol 92:e01243–18

    Article  PubMed  PubMed Central  Google Scholar 

  32. Durrant JD, Kochanek SE, Casalino L et al (2020) Mesoscale all-atom influenza virus simulations suggest new substrate binding mechanism. ACS Cent Sci 6:189–196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Taylor NR, von Itzstein M (1994) Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J Med Chem 37:616–624

    Article  CAS  PubMed  Google Scholar 

  34. Vavricka CJ, Liu Y, Kiyota H et al (2013) Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors. Nat Commun 4:1491

    Article  PubMed  Google Scholar 

  35. Russell RJ, Haire LF, Stevens DJ et al (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45–49

    Article  CAS  PubMed  Google Scholar 

  36. Amaro RE, Swift RV, Votapka L et al (2011) Mechanism of 150-cavity formation in influenza neuraminidase. Nat Commun 2:388

    Article  PubMed  Google Scholar 

  37. Edmond JD, Johnston RG, Kidd D et al (1966) The inhibition of neuraminidase and antiviral action. Br J Pharmacol Chemother 27:415–426

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Meindl P, Tuppy H (1969) 2-Deoxy-2,3-dehydrosialic acids. I. Synthesis and properties of 2-deoxy-2,3-dehydro-N-acylneuraminic acids and their methyl esters. Monatsh Chem 100:1295–1306

    Article  CAS  Google Scholar 

  39. Meindl P, Bodo G, Palese P et al (1974) Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 58:457–463

    Article  CAS  PubMed  Google Scholar 

  40. Palese P, Schulman JL, Bodo G et al (1974) Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA). Virology 59:490–498

    Article  CAS  PubMed  Google Scholar 

  41. Colman PM, Varghese JN, Laver WG (1983) Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41–44

    Article  CAS  PubMed  Google Scholar 

  42. Varghese JN, Smith PW, Sollis SL et al (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6:735–746

    Article  CAS  PubMed  Google Scholar 

  43. Varghese JN, McKimm-Breschkin JL, Caldwell JB et al (1992) The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327–332

    Article  CAS  PubMed  Google Scholar 

  44. Sriwilaijaroen N, Magesh S, Imamura A et al (2016) A novel potent and highly specific inhibitor against influenza viral N1-N9 neuraminidases: insight into neuraminidase-inhibitor interactions. J Med Chem 59:4563–4577

    Article  CAS  PubMed  Google Scholar 

  45. PHE Website (2019) PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/833572/PHE_guidance_antivirals_influenza_201920.pdf

  46. von Itzstein M (2007) The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 6:967–974

    Article  Google Scholar 

  47. Cass LM, Efthymiopoulos C, Bye A (1999) Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 36(Suppl 1):1–11

    Article  CAS  PubMed  Google Scholar 

  48. Lew W, Chen X, Kim CU (2000) Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr Med Chem 7:663–672

    Article  CAS  PubMed  Google Scholar 

  49. Wu Y, Qin G, Gao F et al (2013) Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. Sci Rep 3:1551

    Article  PubMed  PubMed Central  Google Scholar 

  50. Chand P, Kotian PL, Dehghani A et al (2001) Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. J Med Chem 44:4379–4392

    Article  CAS  PubMed  Google Scholar 

  51. Barroso L, Treanor J, Gubareva L et al (2005) Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 10:901–910

    Article  CAS  PubMed  Google Scholar 

  52. Alame MM, Massaad E, Zaraket H (2016) Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections. Front Microbiol 7:450

    Article  PubMed  PubMed Central  Google Scholar 

  53. PDR Website (2021) Peramivir – drug summary. https://www.pdr.net/drug-summary/Rapivab-peramivir-3660

  54. Ison MG (2013) Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses 7:7–13

    Article  CAS  PubMed  Google Scholar 

  55. Watanabe A, Chang SC, Kim MJ et al (2010) Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 51:1167–1175

    Article  CAS  PubMed  Google Scholar 

  56. Koyama K, Nakai D, Takahashi M et al (2013) Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate. Drug Metab Dispos 41:180–187

    Article  CAS  PubMed  Google Scholar 

  57. Magesh S, Sriwilaijaroen N, Moriya S et al (2011) Evaluation of a set of C9 N-acyl Neu5Ac2en mimetics as viral sialidase selective inhibitors. Int J Med Chem 2011:539245

    PubMed  Google Scholar 

  58. Wu Y, Gao F, Qi J et al (2016) Resistance to mutant group 2 influenza virus neuraminidases of an oseltamivir-zanamivir hybrid inhibitor. J Virol 90:10693–10700

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kerry PS, Mohan S, Russell RJ et al (2013) Structural basis for a class of nanomolar influenza A neuraminidase inhibitors. Sci Rep 3:2871

    Article  PubMed  PubMed Central  Google Scholar 

  60. Hata K, Koseki K, Yamaguchi K et al (2008) Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. Antimicrob Agents Chemother 52:3484–3491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Li Z, Meng Y, Xu S et al (2017) Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors. Bioorg Med Chem 25:2772–2781

    Article  CAS  PubMed  Google Scholar 

  62. Watts AG, Damager I, Amaya ML et al (2003) Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: tyrosine is the catalytic nucleophile. J Am Chem Soc 125:7532–7533

    Article  CAS  PubMed  Google Scholar 

  63. Newstead SL, Potter JA, Wilson JC et al (2008) The structure of Clostridium perfringens NanI sialidase and its catalytic intermediates. J Biol Chem 283:9080–9088

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Kim JH, Resende R, Wennekes T et al (2013) Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity. Science 340:71–75

    Article  CAS  PubMed  Google Scholar 

  65. Dirr L, El-Deeb IM, Guillon P et al (2015) The catalytic mechanism of human parainfluenza virus type 3 haemagglutinin-neuraminidase revealed. Angew Chem Int Ed Engl 54:2936–2940

    Article  CAS  PubMed  Google Scholar 

  66. Vavricka CJ, Muto C, Hasunuma T et al (2017) Synthesis of sulfo-sialic acid analogues: potent neuraminidase inhibitors in regards to anomeric functionality. Sci Rep 7:8239

    Article  PubMed  PubMed Central  Google Scholar 

  67. Hadhazi A, Pascolutti M, Bailly B et al (2017) A sialosyl sulfonate as a potent inhibitor of influenza virus replication. Org Biomol Chem 15:5249–5253

    Article  CAS  PubMed  Google Scholar 

  68. Hadhazi A, Li L, Bailly B et al (2018) A sulfonozanamivir analogue has potent anti-influenza virus activity. ChemMedChem 13:785–789

    Article  CAS  PubMed  Google Scholar 

  69. Sasaki K, Nishida Y, Kambara M et al (2004) Design of N-acetyl-6-sulfo-b-D-glucosaminide-based inhibitors of influenza virus sialidase. Bioorg Med Chem 12:1367–1375

    Article  CAS  PubMed  Google Scholar 

  70. Rudrawar S, Dyason JC, Rameix-Welti MA et al (2010) Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat Commun 1:113

    Article  PubMed  Google Scholar 

  71. Rudrawar S, Kerry PS, Rameix-Welti MA et al (2012) Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility. Org Biomol Chem 10:8628–8639

    Article  CAS  PubMed  Google Scholar 

  72. Hsu KC, Hung HC, HuangFu WC et al (2017) Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains. Sci Rep 7:12336

    Article  PubMed  PubMed Central  Google Scholar 

  73. Jia R, Zhang J, Ai W et al (2019) Design, synthesis and biological evaluation of “Multi-Site”-binding influenza virus neuraminidase inhibitors. Eur J Med Chem 178:64–80

    Article  CAS  PubMed  Google Scholar 

  74. Jia R, Zhang J, Bertagnin C et al (2021) Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity. Eur J Med Chem 212:113097

    Article  CAS  PubMed  Google Scholar 

  75. Ai W, Zhang J, Zalloum WA et al (2020) Discovery of novel “dual-site” binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors. Eur J Med Chem 191:112147

    Article  CAS  PubMed  Google Scholar 

  76. Wang HX, Zeng MS, Ye Y et al (2021) Antiviral activity of puerarin as potent inhibitor of influenza virus neuraminidase. Phytother Res 35:324–336

    Article  CAS  PubMed  Google Scholar 

  77. Fu L, Bi Y, Wu Y et al (2016) Structure-based tetravalent zanamivir with potent inhibitory activity against drug-resistant influenza viruses. J Med Chem 59:6303–6312

    Article  CAS  PubMed  Google Scholar 

  78. Liu X, Zhang B, Wang Y et al (2020) A universal dual mechanism immunotherapy for the treatment of influenza virus infections. Nat Commun 11:5597

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Sriwilaijaroen N, Suzuki Y (2014) Molecular basis of a pandemic of avian-type influenza virus. Methods Mol Biol 1200:447–480

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Yu Y, Qin HJ, Shi XX et al (2020) Thiosialoside-decorated polymers use a two-step mechanism to inhibit both early and late stages of influenza virus infection. Eur J Med Chem 199:112357

    Article  CAS  PubMed  Google Scholar 

  81. Li M, Cheng LP, Pang W et al (2020) Design, synthesis, and biological evaluation of novel acylhydrazone derivatives as potent neuraminidase inhibitors. ACS Med Chem Lett 11:1745–1750

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Chen YQ, Lan LY, Huang M et al (2019) Hemagglutinin stalk-reactive antibodies interfere with influenza virus neuraminidase activity by steric hindrance. J Virol 93:e01526-18

    Article  PubMed  PubMed Central  Google Scholar 

  83. Xiong FF, Liu XY, Gao FX et al (2020) Protective efficacy of anti-neuraminidase monoclonal antibodies against H7N9 influenza virus infection. Emerg Microbes Infect 9:78–87

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Stadlbauer D, Zhu X, McMahon M et al (2019) Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366:499–504

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Sriwilaijaroen N, Wilairat P, Hiramatsu H et al (2009) Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities. Virol J 6:124

    Article  PubMed  PubMed Central  Google Scholar 

  86. Gottardi W (1999) Iodine and disinfection: theoretical study on mode of action, efficiency, stability, and analytical aspects in the aqueous system. Arch Pharm (Weinheim) 332:151–157

    Article  CAS  Google Scholar 

  87. Ito H, Ito T, Hikida M et al (2006) Outbreak of highly pathogenic avian influenza in Japan and anti-influenza virus activity of povidone-iodine products. Dermatology 212(Suppl 1):115–118

    Article  CAS  PubMed  Google Scholar 

  88. Priyanka S, Gupta E, Neha M et al (2020) Chapter 16: Shikimic acid as intermediary model for the production of drugs effective against influenza virus. In: Egbuna C, Kumar S, Ifemeje JC, Ezzat SM, Kaliyaperumal S (eds) Phytochemicals as lead compounds for new drug discovery. Elsevier, pp 245–256

    Chapter  Google Scholar 

  89. Sriwilaijaroen N, Kadowaki A, Onishi Y et al (2011) Mumefural and related HMF derivatives from Japanese apricot fruit juice concentrate show multiple inhibitory effects on pandemic influenza A (H1N1) virus. Food Chem 127:1–9

    Article  CAS  Google Scholar 

  90. Sriwilaijaroen N, Fukumoto S, Kumagai K et al (2012) Antiviral effects of Psidium guajava Linn. (guava) tea on the growth of clinical isolated H1N1 viruses: its role in viral hemagglutination and neuraminidase inhibition. Antivir Res 94:139–146

    Article  CAS  PubMed  Google Scholar 

  91. Song JM, Lee KH, Seong BL (2005) Antiviral effect of catechins in green tea on influenza virus. Antivir Res 68:66–74

    Article  CAS  PubMed  Google Scholar 

  92. Kim YS, Li W, Kim JH et al (2020) Anti-influenza activity of an ethyl acetate fraction of a Rhus verniciflua ethanol extract by neuraminidase inhibition. Oxidative Med Cell Longev 2020:8824934

    Article  Google Scholar 

  93. de Freitas CS, Rocha MEN, Sacramento CQ et al (2020) Agathisflavone, a biflavonoid from Anacardium occidentale L., inhibits influenza virus neuraminidase. Curr Top Med Chem 20:111–120

    Article  PubMed  Google Scholar 

  94. Luo S, Guo L, Sheng C et al (2020) Rapid identification and isolation of neuraminidase inhibitors from mockstrawberry (Duchesnea indica Andr.) based on ligand fishing combined with HR-ESI-Q-TOF-MS. Acta Pharm Sin B 10:1846–1855

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Li P, Du R, Chen Z et al (2021) Punicalagin is a neuraminidase inhibitor of influenza viruses. J Med Virol 93:3465–3472

    Article  CAS  PubMed  Google Scholar 

  96. Li P, Du R, Wang Y et al (2020) Identification of chebulinic acid and chebulagic acid as novel influenza viral neuraminidase inhibitors. Front Microbiol 11:182

    Article  PubMed  PubMed Central  Google Scholar 

  97. Grienke U, Schmidtke M, Kirchmair J et al (2010) Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem 53:778–786

    Article  CAS  PubMed  Google Scholar 

  98. Lai Y, Yan Y, Liao S et al (2020) 3D-quantitative structure-activity relationship and antiviral effects of curcumin derivatives as potent inhibitors of influenza H1N1 neuraminidase. Arch Pharm Res 43:489–502

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Hahm HS, Toroitich EK, Borne AL et al (2020) Global targeting of functional tyrosines using sulfur-triazole exchange chemistry. Nat Chem Biol 16:150–159

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Preclinical Sciences, Faculty of Medicine, Thammasat University, Pathumthani, Thailand

    Nongluk Sriwilaijaroen

  2. Department of Medical Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

    Nongluk Sriwilaijaroen & Yasuo Suzuki

  3. Graduate School of Science, Technology and Innovation, Kobe University, Kobe, Japan

    Christopher J. Vavricka

  4. Graduate School of Environmental and Life Science, Okayama University, Okayama, Japan

    Hiromasa Kiyota

Authors
  1. Nongluk Sriwilaijaroen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. Vavricka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiromasa Kiyota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuo Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasuo Suzuki .

Editor information

Editors and Affiliations

  1. Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences, Shizuoka, Japan

    Yasuo Suzuki

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Sriwilaijaroen, N., Vavricka, C.J., Kiyota, H., Suzuki, Y. (2022). Influenza A Virus Neuraminidase Inhibitors. In: Suzuki, Y. (eds) Glycovirology. Methods in Molecular Biology, vol 2556. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2635-1_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-2635-1_21

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-2634-4

  • Online ISBN: 978-1-0716-2635-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation